Гігієнічні аспекти відновлення відкритих техногенних бедлендів із застосуванням осадів міських стічних вод

Зростання індивідуального водоспоживання у великих містах породжує проблему утворення і розміщення на території населених пунктів значної кількості осадів стічних вод. Часто вони представляють епідемічну небезпеку для людини і с джерелом потрапляння у довкілля техногенних хімічних речовин. На основі санітарно-гігієнічної оцінки осадів комунальних стічних вод м. Кривого Рогу розглядається можливість і даються рекомендації для її безпечного використання при створенні вторинних природних ландшафтів у місцях «місячних поверхонь» після відкритого видобутку залізної руди.Рост индивидуального водопотребления в крупных городах порождает проблему образования и размещения на территории населенных пунктов значительного количества осадков сточных вод. Часто они представляют эпидемическую опасность для человека и являются источником поступления в окружающую среду техногенных химических веществ. На основе санитарно-гигиенической оценки осадков коммунальных сточных вод г. Кривого Рога рассматривается возможность и даются рекомендации для их безопасного использования при создании вторичных природных ландшафтов в местах «лунных поверхностей» после открытой добычи железной руды.Growth of individual water consumption in large cities generates a problem of formation and placing of a considerable quantity of deposits of sewage. Often they represent epidemic danger to the person and are a receipt source in environment of technogenic chemical substances. On the basis of a sanitary-and-hygienic estimation of deposits of sewage in a city* of Krivoi Rig consider possibility and definition of the recommendation for safe use of deposits at creation of secondary natural landscapes in places of open-pit mining of iron ore

Comparison of SARS-CoV-2-Specific Antibodies in Human Milk after mRNA-Based COVID-19 Vaccination and Infection

SARS-CoV-2-specific antibodies are secreted into human milk of infected or vaccinated lactating women and might provide protection to the breastfed infant against COVID-19. Differences in antibody response after these types of exposure are unknown. In this longitudinal cohort study, we compared the antibody response in human milk following SARS-CoV-2 vaccination or infection. We analyzed 448 human milk samples of 28 lactating women vaccinated with the SARS-CoV-2 vaccine BNT162b2 as well as 82 human milk samples of 18 lactating women with a prior SARS-CoV-2 infection. The levels of SARS-CoV-2-specific IgA in human milk were determined over a period of 70 days both after vaccination and infection. The amount of SARS-CoV-2-specific IgA in human milk was similar after SARS-CoV-2 vaccination and infection. After infection, the variability in IgA levels was higher than after vaccination. Two participants with detectable IgA prior to vaccination were analyzed separately and showed higher IgA levels following vaccination compared to both groups. In conclusion, breastfed infants of mothers who have been vaccinated with the BNT162b2 vaccine receive human milk with similar amounts of SARS-CoV-2-specific antibodies compared to infants of previously infected mothers

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: The impact of expensive chemotherapy

__Abstract__ Asparaginase is an expensive drug, but important in childhood acute lymphoblastic leukemia. In order to compare costs of PEGasparaginase, Erwinia asparaginase and native E. coli asparaginase, we performed a cost-analysis in the Dutch Childhood Oncology Group ALL-10 medium-risk group intensification protocol. Treatment costs were calculated based on patient level data of 84 subjects, and were related to the occurrence of allergy to PEGasparaginase. Simultaneously, decision tree and sensitivity analyses were conducted. The total costs of the intensification course of 30 weeks were $57,893 in patients without PEGasparaginase allergy (n=64). The costs were significantly higher ($113,558) in case of allergy (n=20) necessitating a switch to Erwinia asparaginase. Simulated scenarios (decision tree analysis) using native E. coli asparaginase in intensification showed that the costs of PEGasparaginase were equal to those of native E. coli asparaginase. Also after sensitivity analyses, the costs for PEGasparaginase were equal to those of na

Cancer related maternal mortality and delay in diagnosis and treatment: A case series on 26 cases

Background: Cancer during pregnancy is relatively rare but may lead to maternal mortality. We aimed to assess the incidence of cancer related maternal mortality and the neonatal outcome in these patients. Also, doctor- and patient-related delay in cancer diagnosis and therapy among patients with cancer related maternal mortality is assessed. Methods: Maternal mortality was defined as death during pregnancy or within 1 year after delivery. Data of the Dutch Maternal Mortality Committee was used to calculate the cancer related maternal mortality rate and to assess neonatal outcome in the Netherlands. Delay was scored by ten medical specialist based on case descriptions. Results: Cancer related maternal mortality rate was 1.23 per 100,000 live births. Delay in either diagnosis or treatment occurred in 65%. Delay in diagnosis was more frequent then delay in treatment, and was mainly caused by health care providers. Only 77% of pregnancies were ongoing, and 65% ended preterm of which 85% was induced. Conclusions: Avoiding delay in diagnosis and therapy in case of pregnancy related cancer could potentially improve maternal and neonatal outcome. It is therefore essential to increase awareness among health care providers about the occurrence and recurrence of cancer in pregnancy and the possibilities of diagnostic and therapeutic interventions in these women